Cysteine and Folate Metabolism Are Targetable Vulnerabilities of Metastatic Colorectal Cancer
Authors:
- Josep Tarragó-CeladaJTJosep Tarragó-Celada
- Carles FoguetCFCarles Foguet
- Míriam Tarrado-CastellarnauMTMíriam Tarrado-Castellarnau
- Silvia MarinSilvia Marin
- Xavier Hernández-AliasXHXavier Hernández-Alias
- Jordi PerarnauJPJordi Perarnau
- Fionnuala MorrishFMFionnuala Morrish
- David HockenberyDHDavid Hockenbery
- Roger R. GomisRGRoger R. Gomis
- Eytan RuppinEREytan Ruppin
- Mariia YunevaMYMariia Yuneva
- Pedro de AtauriPAPedro de Atauri
Open Access
Abstract
With most cancer-related deaths resulting from metastasis, the development of new therapeutic approaches against metastatic colorectal cancer (mCRC) is essential to increasing patient survival. The metabolic adaptations that support mCRC remain undefined and their elucidation is crucial to identify potential therapeutic targets. Here, we employed a strategy for the rational identification of targetable metabolic vulnerabilities. This strategy involved first a thorough metabolic characterisation of same-patient-derived cell lines from primary colon adenocarcinoma (SW480), its lymph node metastasis (SW620) and a liver metastatic derivative (SW620-LiM2), and second, using a novel multi-omics integration workflow, identification of metabolic vulnerabilities specific to the metastatic cell lines. We discovered that the metastatic cell lines are selectively vulnerable to the inhibition of cystine import and folate metabolism, two key pathways in redox homeostasis. Specifically, we identified the system xCT and MTHFD1 genes as potential therapeutic targets, both individually and combined, for combating mCRC.Keywords
Funding Information
- Agència de Gestió d'Ajuts Universitaris i de Recerca (2017SGR1033)
- Institució Catalana de Recerca i Estudis Avançats (MC)
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (SAF2017-89673-R)
- Francis Crick Institute (FC001223)
- Medical Research Council (FC001223)
- Wellcome Trust (FC001223)
- National Institutes of Health (5R01 CA158921-04)
This publication has 74 references indexed in Scilit:
- Microtubule S-glutathionylation as a potential approach for antimitotic agentsBMC Cancer, 2012
- The AntifolatesHematology/Oncology Clinics of North America, 2012
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- System xc‐ cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNSBritish Journal of Pharmacology, 2011
- Pathophysiology and treatment of cystinuriaNature Reviews Nephrology, 2010
- Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiationFree Radical Biology and Medicine, 2009
- Characterization of a Novel Dithiocarbamate Glutathione Reductase Inhibitor and Its Use as a Tool to Modulate Intracellular GlutathioneJournal of Biological Chemistry, 2009
- Context-Specific Metabolic Networks Are Consistent with ExperimentsPLOS Computational Biology, 2008
- Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasisCarcinogenesis, 2006
- Validation of a model of colon cancer progressionThe Journal of Pathology, 2000